The Humira Biosimilar Market is estimated to be valued at US$ 772.1 Million In 2023 and is expected to exhibit a CAGR of 25.9% over the forecast period 2023 - 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview:Humira is a monoclonal antibody used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic...
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian